Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.35 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL27191662 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL17113855 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL756553 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL29092653 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL756554 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL139231 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| D-Leucine SCHEMBL1537225 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL139230 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL17113857 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL8817376 | 0.97 | SLC7A5 (0.51) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160143900-A1 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | OYAGEN, INC. (US) | 2016-05-26 | — | — | US | claimed |
| US-20150272959-A1 | SMALL MOLECULES AS ANTI-HIV AGENTS THAT DISRUPT VIF SELF-ASSOCIATION AND METHODS OF USE THEREOF | OYAGEN, INC. (US) | 2015-10-01 | — | — | US | claimed |
| EP-2903611-A1 | SMALL MOLECULES AS ANTI-HIV AGENTS THAT DISRUPT VIF SELF-ASSOCIATION AND METHODS OF USE THEREOF | Oyagen Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| WO-2014210082-A2 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | OYAGEN, INC. (US) | 2014-12-31 | — | — | WO | claimed |
| WO-2014055944-A1 | SMALL MOLECULES AS ANTI-HIV AGENTS THAT DISRUPT VIF SELF-ASSOCIATION AND METHODS OF USE THEREOF | OYAGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| US-20220000860-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11116762-B2 | Compounds, compositions, and methods for treating human immunodeficiency virus | OYAGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200338067-A1 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | OYAGEN, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10588902-B2 | Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association | OYAGEN, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190350925-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3565554-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | Oyagen, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018128993-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2014210082-A2 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | OYAGEN, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014055944-A1 | SMALL MOLECULES AS ANTI-HIV AGENTS THAT DISRUPT VIF SELF-ASSOCIATION AND METHODS OF USE THEREOF | OYAGEN, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| US-20080124275-A1 | Crystalline Form of Fatty Acid Amide Hydrolase (Faah) | THE SCRIPPS RESEARCH INSTITUTE | 2008-05-29 | — | — | US | disclosed |
| EP-1576127-A4 | CRYSTALLINE FORM OF FATTY ACID AMINE HYDROLASE (FAAH) | SCRIPPS RESEARCH INST (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1576127-A2 | CRYSTALLINE FORM OF FATTY ACID AMINE HYDROLASE (FAAH) | The Scripps Research Institute (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1576127-A3 | CRYSTALLINE FORM OF FATTY ACID AMINE HYDROLASE (FAAH) | The Scripps Research Institute (US) | 2005-08-11 | — | — | EP | disclosed |
| WO-2004044169-A9 | CRYSTALLINE FORM OF FATTY ACID AMINE HYDROLASE (FAAH) | SCRIPPS RESEARCH INST (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004044169-A2 | CRYSTALLINE FORM OF FATTY ACID AMINE HYDROLASE (FAAH) | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588902-B2 | Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association | REV1, APOBEC3A, TOP2A | SLC7A5 4217/4885SLC1A3 3369/4885SLC1A2 3954/4885 |
| US-20190350925-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | HAVCR2, TTPA, CD4 | SLC7A5 2306/4885SLC1A3 3199/4885SLC1A2 3657/4885 |
| US-11116762-B2 | Compounds, compositions, and methods for treating human immunodeficiency virus | HAVCR2, TTPA, CD4 | SLC7A5 2306/4885SLC1A3 3199/4885SLC1A2 3657/4885 |
| US-20220000860-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | HAVCR2, TTPA, CD4 | SLC7A5 2306/4885SLC1A3 3199/4885SLC1A2 3657/4885 |
| US-20160143900-A1 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | REV1, APOBEC3A, TOP2A | SLC7A5 4217/4885SLC1A3 3369/4885SLC1A2 3954/4885 |
| US-20200338067-A1 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | REV1, APOBEC3A, TOP2A | SLC7A5 4217/4885SLC1A3 3369/4885SLC1A2 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.